Unorthodox Ventures
VC Fund
Austin, United States
Unorthodox Ventures is a complete reinvention of the broken and parasitic investment process. Founded by contrarian entrepreneur Carey Smith who bootstrapped Big Ass Fans to a $500 million sale, the company is seeking to partner with founders who demonstrate disruption and discipline. Unlike most investors, Unorthodox Ventures shuns financiers andinstead is filled with people who have actually operated companies and know how to grow them.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Unorthodox Ventures invests in
Stages Unorthodox Ventures invests in
Countries Unorthodox Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Investment Focus
Industry
- Health Care 11 (50%)
- Medical Device 9 (41%)
- Medical 8 (36%)
- Retail 3 (14%)
- Fitness 3 (14%)
Stage
- Series B 5 (23%)
- Series A 4 (18%)
- Venture - Series Unknown 4 (18%)
- Seed 3 (14%)
- Series C 2 (9%)
Country
- United States 11 (50%)
- Israel 3 (14%)
- Germany 2 (9%)
- Switzerland 2 (9%)
- France 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Carey Smith
Founding Contrarian
|
Founding Contrarian | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $120M / Series E / Mar 26, 2025 | |
Laplace Interventional
|
Laplace developing Transcatheter Tricuspid Valve Technology to offer an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation. | $22M / Series C / Mar 16, 2025 | |
Sonavex
|
Sonavex is committed to improving outcomes for surgical patients by using cutting-edge imaging technology to provide clinicians with visualization of critical data -- directly at the point of care. The company's technology offers a proprietary technology platform that utilizes ultrasound to detect blood clots after surgery, enabling cliniciansto measure critical intravascular flow metrics to detect post-operative clots directly at the point of care and improve outcomes. | $15M / Series A / Oct 24, 2024 | |
CorFlow Therapeutics
|
CorFlow Therapeutics is a medtech startup that develops proprietary technologies for diagnosis and treatment of microvascular obstructions in heart attack patients. The CorFlow technologies enable interventional cardiologists to diagnose and treat MVO in severe heart attack patients thereby potentially reducing the short- and long-term complicationrates in these patients. | $48.5M / Series B / Sep 10, 2024 | |
Adona Medical
|
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $33.5M / Series C / Jul 10, 2024 | |
FIRMUS
|
FIRMUS is making construction companies more profitable by automatically uncovering hidden design risks with great impact on bidding and building processes.In addition to protecting contractors' profit margins, FIRMUS creates a significant competitive advantage for contractors by improving relationships with owners from the very early stagesof the project and increasing the number of repeat customers.FIRMUS vision is becoming an industry standard, allowing contractors and owners worldwide to assess and manage design risk and opportunities in all project phases. | Venture - Series Unknown / May 15, 2024 | |
ConKay Medical Systems
|
ConKay Medical Systems is an early-stage medical device company advancing solutions to treat valvular regurgitation in patients with progressive heart failure. | $1.8M / Seed / Mar 18, 2024 | |
Laza Medical
|
Laza Medical is a privately held startup focused on producing a high-quality AI-powered robotic imaging solution for cardiovascular treatments. | $36M / Series A / Dec 12, 2023 | |
CarThera
|
CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders since.The company’s proprietary device called SonoCloud® is an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB) and allows a significantly increased concentration of therapeutic molecules to reachthe brain. | $4.8M / Series B / Dec 11, 2023 | |
Corporis Medical
|
Corporis Medical is a young medical device company. They develop and commercialize innovative medical devices. They also lower the costs associated with surgery and surgical procedures for surgeons. They improve access, closure and diagnostic measurements. | $4.3M / Series B / Dec 07, 2023 | |
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Unorthodox Ventures invest in?
Unorthodox Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Series A stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Unorthodox Ventures?
Public channels for Unorthodox Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Unorthodox Ventures?
The team at Unorthodox Ventures includes Carey Smith (Founding Contrarian). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
